EORTC-1416-LCG/ETOP 8–15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use - O’Brien, MER; Paz-Ares, L; Jha, N (Journal of Clinical Oncology, 2022)